decision
Doxecitine and Doxribtimine in the treatment of thymidine kinase 2 deficiency (TK2d)
Published 2026-07-07.
Doxecitine and Doxribtimine in the treatment of paediatric and adult patients with thymidine kinase 2 deficiency (TK2d) with an age of symptom onset on or before 12 years.
§ Publishing organisations